A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Inclusion Criteria

• Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.

• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.

• Eastern Cooperative Oncology Group Performance Status of 0 or 1.

• Radiographically documented progressive disease on or after the most recent therapy.

• Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.

• Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.

Exclusion Criteria

• Women who are pregnant or breastfeeding.

• Primary central nervous system (CNS) malignancy.

• Untreated CNS metastases.

• Leptomeningeal metastases.

• Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment.

• Active, known, or suspected autoimmune disease.

• Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment.

• Prior organ or tissue allograft.

• Uncontrolled or significant cardiovascular disease.

• Major surgery within 4 weeks of study drug administration.

• History of or with active interstitial lung disease or pulmonary fibrosis.

Other protocol-defined inclusion/exclusion criteria apply